Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Epithelial IL-33 appropriates exosome trafficking for secretion in chronic airway disease
Ella Katz-Kiriakos, … , Mark J. Miller, Jennifer Alexander-Brett
Ella Katz-Kiriakos, … , Mark J. Miller, Jennifer Alexander-Brett
Published January 28, 2021
Citation Information: JCI Insight. 2021;6(4):e136166. https://doi.org/10.1172/jci.insight.136166.
View: Text | PDF
Research Article Immunology Pulmonology

Epithelial IL-33 appropriates exosome trafficking for secretion in chronic airway disease

  • Text
  • PDF
Abstract

IL-33 is a key mediator of chronic airway disease driven by type 2 immune pathways, yet the nonclassical secretory mechanism for this cytokine remains undefined. We performed a comprehensive analysis in human airway epithelial cells, which revealed that tonic IL-33 secretion is dependent on the ceramide biosynthetic enzyme neutral sphingomyelinase 2 (nSMase2). IL-33 is cosecreted with exosomes by the nSMase2-regulated multivesicular endosome (MVE) pathway as surface-bound cargo. In support of these findings, human chronic obstructive pulmonary disease (COPD) specimens exhibited increased epithelial expression of the abundantly secreted IL33Δ34 isoform and augmented nSMase2 expression compared with non-COPD specimens. Using an Alternaria-induced airway disease model, we found that the nSMase2 inhibitor GW4869 abrogated both IL-33 and exosome secretion as well as downstream inflammatory pathways. This work elucidates a potentially novel aspect of IL-33 biology that may be targeted for therapeutic benefit in chronic airway diseases driven by type 2 inflammation.

Authors

Ella Katz-Kiriakos, Deborah F. Steinberg, Colin E. Kluender, Omar A. Osorio, Catie Newsom-Stewart, Arjun Baronia, Derek E. Byers, Michael J. Holtzman, Dawn Katafiasz, Kristina L. Bailey, Steven L. Brody, Mark J. Miller, Jennifer Alexander-Brett

×

Figure 7

nSMase2 inhibition in Alternaria airway disease model.

Options: View larger image (or click on image) Download as PowerPoint
nSMase2 inhibition in Alternaria airway disease model.
(A) Schematic of ...
(A) Schematic of Alternaria experimental model. Mice were treated i.n. with 25 μg Alternaria extract (Alt) or PBS (control) every other day for 9 days. Mice receiving Alt were either treated i.p. with DMSO/saline vehicle control (Alt/D) or GW4869 (Alt/G, 2–2.5 μg/g) daily for 9 days. Some mice were analyzed 1 hour following the last Alt dose; the remainder were analyzed 24 hours after the last dose. (B) Lung tissue qPCR for the 3 groups (n = 3), demonstrating increased Il33 and Smpd3 mRNA with Alt treatment. (C) IL-33 protein quantified by ELISA (normalized to total protein) for lung lysate (n = 3), intracellular fraction (pooled single-cell suspension, n = 3 each), and 1-hour (n = 3) or 24-hour (n = 3) bronchoalveolar lavage (BAL) samples. IL-33 was increased in the intracellular fraction and decreased in BAL with GW4869 treatment. (D) Exosome quantity measured by TRPS for pooled (n = 3) BAL samples with vesicle quantity, representative size distribution (with peak), and CD9 Western blot, reflecting the decrease in BAL vesicle quantity and corresponding CD9 staining with GW4869 treatment. (E) Tissue IL-33 immunofluorescence staining (red) demonstrating increased cytoplasmic IL-33 signal (insets) and expansion of IL-33+ parenchymal cells in Alt groups. DAPI counterstain was also used. Scale bar: 50 μm (gray); 10 μm (white). (F) Lung tissue Il13 and Il5 qPCR (n = 3) demonstrating induction with Alt treatment that was attenuated with GW4869. (G) Representative FACS plots for sorted lung innate lymphoid type 2 cells (ILC2, pooled samples, n = 3) and Il13 qPCR in sorted cells, demonstrating induction of ILC2 cells and IL13 expression with Alt treatment and concomitant reduction with GW4869 treatment. Data are shown as the mean ± SEM. Statistical analysis: 1-way ANOVA (B, C, and F); *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts